BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:DS-1103a readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of DS-1103a\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05765851-7686@assetmemo.bio
DTSTAMP:20261121T005448Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:DS-1103a: Phase 1 readout est. (NCT05765851)
DESCRIPTION:DS-1103a\, phase 1.\nStudy: A Study of DS-1103a Combination The
 rapy in Participants With Advanced Solid Tumors\nEstimated primary complet
 ion: 31 May 2029. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ds-
 1103a#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT05765851
URL:https://assetmemo.bio/drug/ds-1103a#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07739966-7686@assetmemo.bio
DTSTAMP:20261121T005448Z
DTSTART;VALUE=DATE:20300731
DTEND;VALUE=DATE:20300801
SUMMARY:DS-1103a: Phase 1/2 readout est. (NCT07739966)
DESCRIPTION:DS-1103a\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A St
 udy of DS-3939a in Participants With Solid Tumors\nEstimated primary compl
 etion: 31 July 2030. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 ds-1103a#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07739966
URL:https://assetmemo.bio/drug/ds-1103a#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
